Cytomed Therapeutics Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 31, 2026, reports the full-year financial results for the period ended December 31, 2025, along with clinical and corporate updates. Cytomed Therapeutics Ltd is a Singapore-based company developing affordable anti-cancer cell therapies using allogeneic off-the-shelf Gamma Delta T cell technology.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue and Other Operating Income | US$780,857 | US$663,786 |
| Net Loss (Audited) | US$3.11 million | US$1.96 million |
| Adjusted Net Loss (Excl. Non-cash SBC & Public Co Costs) | US$2.12 million | N/A |
| Cash and Bank Balances (Dec 31) | US$1.63 million | US$3.87 million |
| Research Expenses | US$1.72 million | US$1.48 million |
| Employee Benefits Expenses | US$723,667 | US$481,629 |
| Other Expenses | US$1.30 million | US$776,152 |
| Debt (Borrowings for Properties) | US$318,456 | N/A |
Non-Cash Adjustments: The 2025 net loss includes US$539,855 in share-based payment expenses and US$452,092 in public company listing costs.
Material Changes vs. Prior Period
- Liquidity Decline: Cash balances decreased by approximately US$2.24 million (58% drop) from 2024 to 2025.
- Increased Loss: The audited net loss widened by US$1.15 million year-over-year, driven primarily by higher research, employee benefits, and other operating expenses.
- Expense Drivers: Research expenses rose due to higher consumables, employee benefits, and clinical trial costs. Employee benefits increased significantly due to the first share-based compensation award since the 2023 IPO.
- Revenue Growth: Total revenue and other operating income increased by approximately 17.6% year-over-year.
Guidance, Outlook, and Clinical Updates
- Outlook: Management advises navigating 2026 with caution due to global economic volatility but does not currently expect significant impacts from tariffs or Middle East conflicts.
- ANGELICA Trial (Singapore): The Phase I CAR-T trial is proceeding at dose level 2, with escalation to dose level 3 imminent. Completion is targeted for 2026. Six patients have been treated to date.
- Malaysia Expansion: A Memorandum of Understanding with Universiti Malaya aims to launch a Phase I trial for unmodified Gamma Delta T cells (CTM-GDT) for no-option cancer patients. An Investigational New Drug application is targeted for submission before June 2026.
- Strategic Assets: The company acquired assets of a Malaysian cord blood bank via its subsidiary LongevityBank Pte. Ltd. and is setting up an ISO-standard laboratory. An equity investment in a Malaysian medical clinic entity was also made.
- Research Collaboration: A preclinical study co-authored with MD Anderson Cancer Center suggests potential for the company's therapy in treating Acute Myeloid Leukemia (AML).
Investor Verification Checklist
- Verify the burn rate and runway given the 58% reduction in cash balances to US$1.63 million.
- Confirm the timeline for the submission of the Investigational New Drug application in Malaysia (targeted before June 2026).
- Assess the sustainability of revenue growth (US$780k) against the widening net loss (US$3.11m).
- Review the details of the share-based compensation plan and its impact on future dilution.
- Validate the status of the ANGELICA trial patient enrollment and dose escalation progress.